Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

FOXA1 Protein Expression in ER+ and ER- Breast Cancer in Relation to Parity and Breastfeeding in Black and White Women.

Cheng TD, Yao S, Omilian AR, Khoury T, Buas MF, Payne-Ondracek R, Sribenja S, Bshara W, Hong CC, Bandera EV, Davis W, Higgins MJ, Ambrosone CB.

Cancer Epidemiol Biomarkers Prev. 2019 Dec 23. doi: 10.1158/1055-9965.EPI-19-0787. [Epub ahead of print]

PMID:
31871111
2.

TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC).

Bunch B, Krishnan N, Greenspan RD, Ramakrishnan S, Attwood K, Yan L, Qi Q, Wang D, Morrison C, Omilian A, Bshara W, Pili R, Trump DL, Johnson C, Woloszynska A.

Cell Cycle. 2019 Sep;18(17):2055-2066. doi: 10.1080/15384101.2019.1638693. Epub 2019 Jul 18.

PMID:
31318640
3.

Tumor-associated macrophage expression of interferon regulatory Factor-8 (IRF8) is a predictor of progression and patient survival in renal cell carcinoma.

Muhitch JB, Hoffend NC, Azabdaftari G, Miller A, Bshara W, Morrison CD, Schwaab T, Abrams SI.

J Immunother Cancer. 2019 Jun 20;7(1):155. doi: 10.1186/s40425-019-0630-0.

4.

Storage Conditions and Immunoreactivity of Breast Cancer Subtyping Markers in Tissue Microarray Sections.

Omilian AR, Zirpoli GR, Cheng TD, Yao S, Stein L, Davis W, Head KL, Nair P, Khoury T, Ambrosone CB, Bshara W.

Appl Immunohistochem Mol Morphol. 2019 Jun 12. doi: 10.1097/PAI.0000000000000756. [Epub ahead of print]

PMID:
31205070
5.

TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.

Mukhopadhyay UK, Oturkar CC, Adams C, Wickramasekera N, Bansal S, Medisetty R, Miller A, Swetzig WM, Silwal-Pandit L, Børresen-Dale AL, Creighton CJ, Park JH, Konduri SD, Mukhopadhyay A, Caradori A, Omilian A, Bshara W, Kaipparettu BA, Das GM.

J Natl Cancer Inst. 2019 Nov 1;111(11):1202-1215. doi: 10.1093/jnci/djz051.

6.

Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer.

Kumar R, Bhat TA, Walsh EM, Chaudhary AK, O'Malley J, Rhim JS, Wang J, Morrison CD, Attwood K, Bshara W, Mohler JL, Yadav N, Chandra D.

Cancer Res. 2019 Apr 1;79(7):1353-1368. doi: 10.1158/0008-5472.CAN-18-2383. Epub 2019 Feb 14.

PMID:
30765600
7.

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.

Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C.

J Immunother Cancer. 2019 Feb 1;7(1):27. doi: 10.1186/s40425-019-0506-3.

8.

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.

Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Bshara W, Khalil M, Dy GK, Madden KG, Shirai K, Dragnev K, Tafe LJ, Zhu J, Labriola M, Marin D, McCall SJ, Clarke J, George DJ, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, de la Cruz-Merino L, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Kasuganti D, Shah N, Day R, Galluzzi L, Gardner M, Morrison C.

J Immunother Cancer. 2019 Jan 24;7(1):18. doi: 10.1186/s40425-018-0489-5.

9.

KLF9-dependent ROS regulate melanoma progression in stage-specific manner.

Bagati A, Moparthy S, Fink EE, Bianchi-Smiraglia A, Yun DH, Kolesnikova M, Udartseva OO, Wolff DW, Roll MV, Lipchick BC, Han Z, Kozlova NI, Jowdy P, Berman AE, Box NF, Rodriguez C, Bshara W, Kandel ES, Soengas MS, Paragh G, Nikiforov MA.

Oncogene. 2019 May;38(19):3585-3597. doi: 10.1038/s41388-019-0689-6. Epub 2019 Jan 21.

10.

Analysis of mutations in primary and metastatic synovial sarcoma.

Xing Z, Wei L, Jiang X, Conroy J, Glenn S, Bshara W, Yu T, Pao A, Tanaka S, Kawai A, Choi C, Wang J, Liu S, Morrison C, Yu YE.

Oncotarget. 2018 Dec 7;9(96):36878-36888. doi: 10.18632/oncotarget.26416. eCollection 2018 Dec 7.

11.

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.

Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Lenzo FL, Omilian A, Bshara W, Zibelman M, Ghatalia P, Dragnev K, Shirai K, Madden KG, Tafe LJ, Shah N, Kasuganti D, de la Cruz-Merino L, Araujo I, Saenger Y, Bogardus M, Villalona-Calero M, Diaz Z, Day R, Eisenberg M, Anderson SM, Puzanov I, Galluzzi L, Gardner M, Ernstoff MS.

J Immunother Cancer. 2018 May 9;6(1):32. doi: 10.1186/s40425-018-0344-8.

12.

Frequency of breast cancer subtypes among African American women in the AMBER consortium.

Allott EH, Geradts J, Cohen SM, Khoury T, Zirpoli GR, Bshara W, Davis W, Omilian A, Nair P, Ondracek RP, Cheng TD, Miller CR, Hwang H, Thorne LB, O'Connor S, Bethea TN, Bell ME, Hu Z, Li Y, Kirk EL, Sun X, Ruiz-Narvaez EA, Perou CM, Palmer JR, Olshan AF, Ambrosone CB, Troester MA.

Breast Cancer Res. 2018 Feb 6;20(1):12. doi: 10.1186/s13058-018-0939-5.

13.

Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424).

Cheng TD, Darke AK, Redman MW, Zirpoli GR, Davis W, Payne Ondracek R, Bshara W, Omilian AR, Kratzke R, Reid ME, Molina JR, Kolesar JM, Chen Y, MacRae RM, Moon J, Mack P, Gandara DR, Kelly K, Santella RM, Albain KS, Ambrosone CB.

J Natl Cancer Inst. 2018 Jul 1;110(7):734-742. doi: 10.1093/jnci/djx260.

14.

Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors.

Conroy JM, Pabla S, Glenn ST, Burgher B, Nesline M, Papanicolau-Sengos A, Andreas J, Giamo V, Lenzo FL, Hyland FCL, Omilian A, Bshara W, Qin M, He J, Puzanov I, Ernstoff MS, Gardner M, Galluzzi L, Morrison C.

J Mol Diagn. 2018 Jan;20(1):95-109. doi: 10.1016/j.jmoldx.2017.10.001. Epub 2017 Oct 20.

15.

Ki-67 Expression in Breast Cancer Tissue Microarrays: Assessing Tumor Heterogeneity, Concordance With Full Section, and Scoring Methods.

Khoury T, Zirpoli G, Cohen SM, Geradts J, Omilian A, Davis W, Bshara W, Miller R, Mathews MM, Troester M, Palmer JR, Ambrosone CB.

Am J Clin Pathol. 2017 Aug 1;148(2):108-118. doi: 10.1093/ajcp/aqx053.

16.

A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.

Singh AK, Winslow TB, Kermany MH, Goritz V, Heit L, Miller A, Hoffend NC, Stein LC, Kumaraswamy LK, Warren GW, Bshara W, Odunsi K, Matsuzaki J, Abrams SI, Schwaab T, Muhitch JB.

Clin Cancer Res. 2017 Sep 1;23(17):5055-5065. doi: 10.1158/1078-0432.CCR-16-2946. Epub 2017 Jun 19.

17.

Prognostic value of histone chaperone FACT subunits expression in breast cancer.

Attwood K, Fleyshman D, Prendergast L, Paszkiewicz G, Omilian AR, Bshara W, Gurova K.

Breast Cancer (Dove Med Press). 2017 May 3;9:301-311. doi: 10.2147/BCTT.S126390. eCollection 2017.

18.

Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.

Grabosch S, Tseng G, Edwards RP, Lankes HA, Moore K, Odunsi K, Vlad A, Ma T, Strange M, Brozick J, Lugade A, Omilian A, Bshara W, Stuckey AR, Walker JL, Birrer M.

Gynecol Oncol. 2017 Jul;146(1):137-145. doi: 10.1016/j.ygyno.2017.04.008. Epub 2017 May 5.

19.

P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells.

Babagana M, Johnson S, Slabodkin H, Bshara W, Morrison C, Kandel ES.

Mol Carcinog. 2017 May;56(5):1515-1525. doi: 10.1002/mc.22611. Epub 2017 Feb 23.

20.

A four gene signature predictive of recurrent prostate cancer.

Komisarof J, McCall M, Newman L, Bshara W, Mohler JL, Morrison C, Land H.

Oncotarget. 2017 Jan 10;8(2):3430-3440. doi: 10.18632/oncotarget.13837.

21.

Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing.

Paluch BE, Glenn ST, Conroy JM, Papanicolau-Sengos A, Bshara W, Omilian AR, Brese E, Nesline M, Burgher B, Andreas J, Odunsi K, Eng K, He J, Qin M, Gardner M, Galluzzi L, Morrison CD.

Oncotarget. 2017 Jan 10;8(2):3197-3205. doi: 10.18632/oncotarget.13691.

22.

Corrigendum to the inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach [Nucl Med Biol 43 (2016) 215-225].

Cope FO, Abbruzzese B, Sanders J, Metz W, Sturms K, Ralph D, Blue M, Zhang J, Bracci P, Bshara W, Behr S, Maurer T, Williams K, Walker J, Beverly A, Blay B, Damughatla A, Larsen M, Mountain C, Neylon E, Parcel K, Raghuraman K, Ricks K, Rose L, Sivakumar A, Streck N, Wang B, Wasco C, Williams A, Schlesinger LS, Azad A, Rajaram MVS, Jarjour W, Young N, Rosol T, McGrath M.

Nucl Med Biol. 2016 Dec;43(12):837. doi: 10.1016/j.nucmedbio.2016.10.001. No abstract available.

PMID:
27866590
23.

Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease.

Strohl A, Mori K, Akers S, Bshara W, Buttin B, Frederick PJ, Helenowski IB, Morrison CD, Odunsi K, Schink JC, Scholtens DM, Wei JJ, Kim JJ.

J Ovarian Res. 2016 Nov 3;9(1):75.

24.

Pitfalls of improperly procured adjacent non-neoplastic tissue for somatic mutation analysis using next-generation sequencing.

Wei L, Papanicolau-Sengos A, Liu S, Wang J, Conroy JM, Glenn ST, Brese E, Hu Q, Miles KM, Burgher B, Qin M, Head K, Omilian AR, Bshara W, Krolewski J, Trump DL, Johnson CS, Morrison CD.

BMC Med Genomics. 2016 Oct 19;9(1):64.

25.

Harnessing 3D models of mammary epithelial morphogenesis: An off the beaten path approach to identify candidate biomarkers of early stage breast cancer.

Rossetti S, Bshara W, Reiners JA, Corlazzoli F, Miller A, Sacchi N.

Cancer Lett. 2016 Oct 1;380(2):375-83. doi: 10.1016/j.canlet.2016.07.003. Epub 2016 Jul 12.

26.

Tumor Expression of Vitamin D Receptor and Breast Cancer Histopathological Characteristics and Prognosis.

Al-Azhri J, Zhang Y, Bshara W, Zirpoli G, McCann SE, Khoury T, Morrison CD, Edge SB, Ambrosone CB, Yao S.

Clin Cancer Res. 2017 Jan 1;23(1):97-103. doi: 10.1158/1078-0432.CCR-16-0075. Epub 2016 Jul 12.

27.

Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.

Allott EH, Geradts J, Sun X, Cohen SM, Zirpoli GR, Khoury T, Bshara W, Chen M, Sherman ME, Palmer JR, Ambrosone CB, Olshan AF, Troester MA.

Breast Cancer Res. 2016 Jun 28;18(1):68. doi: 10.1186/s13058-016-0725-1.

28.

PRAME expression and promoter hypomethylation in epithelial ovarian cancer.

Zhang W, Barger CJ, Eng KH, Klinkebiel D, Link PA, Omilian A, Bshara W, Odunsi K, Karpf AR.

Oncotarget. 2016 Jul 19;7(29):45352-45369. doi: 10.18632/oncotarget.9977.

29.

Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools.

Bianchi-Smiraglia A, Bagati A, Fink EE, Moparthy S, Wawrzyniak JA, Marvin EK, Battaglia S, Jowdy P, Kolesnikova M, Foley CE, Berman AE, Kozlova NI, Lipchick BC, Paul-Rosner LM, Bshara W, Ackroyd JJ, Shewach DS, Nikiforov MA.

Oncogene. 2017 Jan 5;36(1):84-96. doi: 10.1038/onc.2016.178. Epub 2016 May 16.

30.

Whole-genome sequencing of a malignant granular cell tumor with metabolic response to pazopanib.

Wei L, Liu S, Conroy J, Wang J, Papanicolau-Sengos A, Glenn ST, Murakami M, Liu L, Hu Q, Conroy J, Miles KM, Nowak DE, Liu B, Qin M, Bshara W, Omilian AR, Head K, Bianchi M, Burgher B, Darlak C, Kane J, Merzianu M, Cheney R, Fabiano A, Salerno K, Talati C, Khushalani NI, Trump DL, Johnson CS, Morrison CD.

Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000380. doi: 10.1101/mcs.a000380.

31.

The inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach.

Cope FO, Abbruzzese B, Sanders J, Metz W, Sturms K, Ralph D, Blue M, Zhang J, Bracci P, Bshara W, Behr S, Maurer T, Williams K, Walker J, Beverly A, Blay B, Damughatla A, Larsen M, Mountain C, Neylon E, Parcel K, Raghuraman K, Ricks K, Rose L, Sivakumar A, Streck N, Wang B, Wasco C, Schlesinger LS, Azad A, Rajaram MVS, Jarjour W, Young N, Rosol T, Williams A, McGrath M.

Nucl Med Biol. 2016 Mar;43(3):215-25. doi: 10.1016/j.nucmedbio.2015.11.007. Epub 2015 Dec 3. Review. Erratum in: Nucl Med Biol. 2016 Dec;43(12):837.

32.

Performance of Three-Biomarker Immunohistochemistry for Intrinsic Breast Cancer Subtyping in the AMBER Consortium.

Allott EH, Cohen SM, Geradts J, Sun X, Khoury T, Bshara W, Zirpoli GR, Miller CR, Hwang H, Thorne LB, O'Connor S, Tse CK, Bell MB, Hu Z, Li Y, Kirk EL, Bethea TN, Perou CM, Palmer JR, Ambrosone CB, Olshan AF, Troester MA.

Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):470-8. doi: 10.1158/1055-9965.EPI-15-0874. Epub 2015 Dec 28.

33.

Photodynamic therapy of human lung cancer xenografts in mice.

Nwogu C, Pera P, Bshara W, Attwood K, Pandey R.

J Surg Res. 2016 Jan;200(1):8-12. doi: 10.1016/j.jss.2015.07.024. Epub 2015 Jul 17.

34.

Impact of devascularization and tissue procurement on cell number and RNA integrity in prostatectomy tissue.

Payne Ondracek R, Cheng J, Gangavarapu KJ, Azabdaftari G, Woltz J, Brese E, Omilian A, Bshara W, Huss WJ, Mohler JL, Marshall JR.

Prostate. 2015 Dec;75(16):1910-5. doi: 10.1002/pros.23087. Epub 2015 Sep 9.

35.

Pharmacological targeting of guanosine monophosphate synthase suppresses melanoma cell invasion and tumorigenicity.

Bianchi-Smiraglia A, Wawrzyniak JA, Bagati A, Marvin EK, Ackroyd J, Moparthy S, Bshara W, Fink EE, Foley CE, Morozevich GE, Berman AE, Shewach DS, Nikiforov MA.

Cell Death Differ. 2015 Nov;22(11):1858-64. doi: 10.1038/cdd.2015.47. Epub 2015 Apr 24.

36.

MiR-205 and MiR-375 microRNA assays to distinguish squamous cell carcinoma from adenocarcinoma in lung cancer biopsies.

Patnaik S, Mallick R, Kannisto E, Sharma R, Bshara W, Yendamuri S, Dhillon SS.

J Thorac Oncol. 2015 Mar;10(3):446-53. doi: 10.1097/JTO.0000000000000423.

37.

Characterization of TAZ domains important for the induction of breast cancer stem cell properties and tumorigenesis.

Li YW, Shen H, Frangou C, Yang N, Guo J, Xu B, Bshara W, Shepherd L, Zhu Q, Wang J, Hu Q, Liu S, Morrison CD, Sun P, Zhang J.

Cell Cycle. 2015;14(1):146-56. doi: 10.4161/15384101.2014.967106.

38.

A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.

Kurenova E, Ucar D, Liao J, Yemma M, Gogate P, Bshara W, Sunar U, Seshadri M, Hochwald SN, Cance WG.

Cell Cycle. 2014;13(16):2542-53. doi: 10.4161/15384101.2015.941760.

39.

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.

Köbel M, Madore J, Ramus SJ, Clarke BA, Pharoah PD, Deen S, Bowtell DD, Odunsi K, Menon U, Morrison C, Lele S, Bshara W, Sucheston L, Beckmann MW, Hein A, Thiel FC, Hartmann A, Wachter DL, Anglesio MS, Høgdall E, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Fogarty ZC, Vierkant RA, Liu S, Cho S, Nelson G, Ghatage P, Gentry-Maharaj A, Gayther SA, Benjamin E, Widschwendter M, Intermaggio MP, Rosen B, Bernardini MQ, Mackay H, Oza A, Shaw P, Jimenez-Linan M, Driver KE, Alsop J, Mack M, Koziak JM, Steed H, Ewanowich C, DeFazio A, Chenevix-Trench G, Fereday S, Gao B, Johnatty SE, George J, Galletta L; AOCS Study Group, Goode EL, Kjær SK, Huntsman DG, Fasching PA, Moysich KB, Brenton JD, Kelemen LE.

Br J Cancer. 2014 Dec 9;111(12):2297-307. doi: 10.1038/bjc.2014.567. Epub 2014 Oct 30.

40.

High focal adhesion kinase expression in breast carcinoma is associated with lymphovascular invasion and triple-negative phenotype.

Golubovskaya VM, Ylagan L, Miller A, Hughes M, Wilson J, Wang D, Brese E, Bshara W, Edge S, Morrison C, Cance WG.

BMC Cancer. 2014 Oct 17;14:769. doi: 10.1186/1471-2407-14-769.

41.

The Thoc1 ribonucleoprotein and prostate cancer progression.

Chinnam M, Wang Y, Zhang X, Gold DL, Khoury T, Nikitin AY, Foster BA, Li Y, Bshara W, Morrison CD, Payne Ondracek RD, Mohler JL, Goodrich DW.

J Natl Cancer Inst. 2014 Oct 8;106(11). pii: dju306. doi: 10.1093/jnci/dju306. Print 2014 Nov.

42.

Overexpression of α2,3sialyl T-antigen in breast cancer determined by miniaturized glycosyltransferase assays and confirmed using tissue microarray immunohistochemical analysis.

Patil SA, Bshara W, Morrison C, Chandrasekaran EV, Matta KL, Neelamegham S.

Glycoconj J. 2014 Oct;31(6-7):509-21. doi: 10.1007/s10719-014-9548-4.

43.

The prognostic significance of focal adhesion kinase expression in stage I non-small-cell lung cancer.

Dy GK, Ylagan L, Pokharel S, Miller A, Brese E, Bshara W, Morrison C, Cance WG, Golubovskaya VM.

J Thorac Oncol. 2014 Sep;9(9):1278-84. doi: 10.1097/JTO.0000000000000248.

44.

Oncotype DX RT-qPCR assay for ER and PR correlation with IHC: a study of 3 different clones.

Khoury T, Yan L, Liu S, Bshara W.

Appl Immunohistochem Mol Morphol. 2015 Mar;23(3):178-87. doi: 10.1097/PAI.0000000000000078.

PMID:
24992175
45.

Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer.

Morrison CD, Liu P, Woloszynska-Read A, Zhang J, Luo W, Qin M, Bshara W, Conroy JM, Sabatini L, Vedell P, Xiong D, Liu S, Wang J, Shen H, Li Y, Omilian AR, Hill A, Head K, Guru K, Kunnev D, Leach R, Eng KH, Darlak C, Hoeflich C, Veeranki S, Glenn S, You M, Pruitt SC, Johnson CS, Trump DL.

Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):E672-81. doi: 10.1073/pnas.1313580111. Epub 2014 Jan 27.

46.

The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.

Kurenova E, Liao J, He DH, Hunt D, Yemma M, Bshara W, Seshadri M, Cance WG.

Oncotarget. 2013 Oct;4(10):1632-46.

47.

A purine nucleotide biosynthesis enzyme guanosine monophosphate reductase is a suppressor of melanoma invasion.

Wawrzyniak JA, Bianchi-Smiraglia A, Bshara W, Mannava S, Ackroyd J, Bagati A, Omilian AR, Im M, Fedtsova N, Miecznikowski JC, Moparthy KC, Zucker SN, Zhu Q, Kozlova NI, Berman AE, Hoek KS, Gudkov AV, Shewach DS, Morrison CD, Nikiforov MA.

Cell Rep. 2013 Oct 31;5(2):493-507. doi: 10.1016/j.celrep.2013.09.015. Epub 2013 Oct 17.

48.

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.

Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ.

Lancet Oncol. 2013 Aug;14(9):853-62. doi: 10.1016/S1470-2045(13)70253-5. Epub 2013 Jul 9.

49.

Case-only analyses of the associations between polymorphisms in the metastasis-modifying genes BRMS1 and SIPA1 and breast tumor characteristics, lymph node metastasis, and survival.

Roberts MR, Hong CC, Edge SB, Yao S, Bshara W, Higgins MJ, Freudenheim JL, Ambrosone CB.

Breast Cancer Res Treat. 2013 Jun;139(3):873-85. doi: 10.1007/s10549-013-2601-3. Epub 2013 Jun 16.

50.

Origin of the vasculature supporting growth of primary patient tumor xenografts.

Hylander BL, Punt N, Tang H, Hillman J, Vaughan M, Bshara W, Pitoniak R, Repasky EA.

J Transl Med. 2013 May 3;11:110. doi: 10.1186/1479-5876-11-110.

Supplemental Content

Loading ...
Support Center